Retinoic acid receptor–retinoid X receptor heterodimer (RAR–RXR heterodimer)

The retinoic acid receptor–retinoid X receptor heterodimer is a ligand-dependent nuclear receptor complex that orchestrates transcriptional regulation in response to retinoids. The complex is formed by the dimerization of the retinoic acid receptor (RAR) and the retinoid X receptor (RXR), each of which can exist in three isoforms (α, β, γ). Upon ligand binding (e.g., all-trans or 9-cis retinoic acid), the heterodimer binds to specific DNA sequences called retinoic acid response elements (RAREs), recruiting transcriptional coactivators or corepressors, modulating the transcription of genes involved in development, cell differentiation, and metabolism. RAR/RXR heterodimers have central roles in physiology (especially liver, embryogenesis, immune response) and pathology (cancer, metabolic, inflammatory, and fibrotic conditions), making them important drug targets for approved and investigational ligands. Therapeutic manipulation of this heterodimer requires consideration of its widespread physiological roles and associated safety risks.

Other names

RAR–RXR heterodimerRXR–RAR complexRetinoid receptor heterodimer

Agonists and antagonists bind to either RAR or RXR ligand-binding domain, triggering conformational changes that modulate recruitment of coactivators or corepressors, ultimately activating or repressing target gene transcription. Combinatorial ligand binding (to both RAR and RXR) allows for fine-tuned, context-dependent modulation of transcriptional programs. Histone acetyltransferase and methyltransferase recruitment for chromatin remodeling.